Protocol Ledger

NCT04126681 · Phase II · COMPLETED

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Interventional Phase II clinical trial protocol NCT04126681 sponsored by Ascentage Pharma Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-21 Enrollment: 144 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04126681
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)144 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04126681
Protocol FieldVerified Registry Value
NCT IdentifierNCT04126681
Consolidated Lead SponsorAscentage Pharma Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment144 participants (ACTUAL)
Registered Start Date2019-10-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI